Ultragenyx Pharmaceutical Inc(简称Ultragenyx)近日宣布,其针对鸟氨酸氨甲酰基转移酶(OTC)缺乏症研发的DTX301 AAV8基因疗法,在三期临床研究中取得了36周的积极数据。这一进展标志着该基因疗法在长期疗效与安全性方面展现出令人鼓舞的结果。
Ultragenyx Pharmaceutical Inc(简称Ultragenyx)近日宣布,其针对鸟氨酸氨甲酰基转移酶(OTC)缺乏症研发的DTX301 AAV8基因疗法,在三期临床研究中取得了36周的积极数据。这一进展标志着该基因疗法在长期疗效与安全性方面展现出令人鼓舞的结果。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.